

## Isis Pharmaceuticals to Present at the 24th Annual ROTH Conference

March 5, 2012

CARLSBAD, Calif., March 5, 2012 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (Nasdaq: ISIS), the leader in antisense therapeutics, today announced that management will present a company overview at ROTH's 24th Annual OC Growth Stock Conference on Monday, March 12, 2012 at 9:30 a.m. PT at the Ritz-Carlton Laguna Niguel.

A live audio webcast of the presentation will be available on the "Investors & Media" section of the Company's Web site, [www.isispharm.com](http://www.isispharm.com). A replay of the presentation will be available on the Isis Web site within 48 hours and will be archived for a limited time.

### **ABOUT ISIS PHARMACEUTICALS, INC.**

Isis is exploiting its leadership position in antisense technology to discover and develop novel drugs for its product pipeline and for its partners. Isis' broad pipeline consists of 26 drugs to treat a wide variety of diseases with an emphasis on cardiovascular, metabolic, severe and rare diseases, and cancer. Isis' partner, Genzyme, plans to commercialize Isis' lead product, KYNAMRO, following regulatory approval, which is expected in 2012. Isis' patents provide strong and extensive protection for its drugs and technology. Additional information about Isis is available at [www.isispharm.com](http://www.isispharm.com).

SOURCE Isis Pharmaceuticals, Inc.

Kristina Lemonidis, Director, Corporate Communications , +1-760-603-2490; or Amy Blackley, Ph.D., Assistant Director, Corporate Communications, +1-760-603-2772, both of Isis Pharmaceuticals